Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DDX3X | O00571 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5298423 | 0.92 | PPARA (0.35) | PPARASMPD1NPC1LMNAMAPK1 | |
| SCHEMBL5286375 | 0.86 | EPHX2 (0.35) | SMPD1NPC1LMNATP53TSHR | |
| SCHEMBL5283038 | 0.81 | PPARA (0.46) | PPARAMAPK14SMPD1NPC1LMNA | |
| SCHEMBL5287519 | 0.80 | RAB9A (0.34) | PPARANPC1LMNATSHRMAPK1 | |
| SCHEMBL5285680 | 0.76 | PPARA (0.52) | PPARAMAPK14SMPD1LMNATSHR | |
| SCHEMBL5289527 | 0.73 | SCD (0.31) | SMPD1NPC1LMNATP53RAB9A | |
| SCHEMBL5966730 | 0.72 | SMN1; SMN2 (0.41) | PPARASMPD1NPC1TSHRMAPK1 | |
| SCHEMBL5966687 | 0.71 | SMN1; SMN2 (0.40) | MAPK14LMNAMAPTALDH1A1 | |
| SCHEMBL5966739 | 0.71 | ALDH1A1 (0.40) | MAPK14NPC1TSHRRAB9AALDH1A1 | |
| SCHEMBL7500491 | 0.71 | PPARA (0.61) | PPARASMPD1MAPTMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | PPARA 2245/4885MAPK14 2521/4885SMPD1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.